JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
Low Dose / Metronomic Chemotherapy | Lifespring Cancer Treatment Center
Frontiers | Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance
Metronomic Chemotherapy FAQs for Tripawds
Clinical overview of metronomic chemotherapy in breast cancer | Nature Reviews Clinical Oncology
Cancers | Free Full-Text | Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment
Chapter 24.3 metronomic chemotherapy
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health
Metronomic Chemotherapy: New Rationale for New Directions
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?: Trends in Cancer
Metronomic chemotherapy: new rationale for new directions | Nature Reviews Clinical Oncology
Metronomic chemotherapy in non‑small cell lung cancer (Review)
Mechanisms of action of metronomic chemotherapy. The beneficial effects... | Download Scientific Diagram
Current achievements and future perspectives of metronomic chemotherapy | SpringerLink
Role of vascular normalization in benefit from metronomic chemotherapy | PNAS
JCM | Free Full-Text | Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
Metronomic chemotherapy in non-small-cell lung cancer — current status | Semantic Scholar
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development | Future Oncology
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance - ScienceDirect
Metronomic chemotherapy - Rituparna Maiti, 2014
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. - Abstract - Europe PMC
The Ralph CPD Digest - Medical Oncology - The Ralph
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health
